Skip to main content

Galante Joseph C's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) · filed Dec 23, 2022

Accession no.
0001209191-22-062651
Filed
Dec 23, 2022
Trade date
Dec 1-21, 2022
Filing delay
22 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 15 non-derivative transactions. Open-market purchases total $3.45K. It was filed 22 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Galante Joseph CCIK 0001632384Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 1, 2022Common StockPPurchaseAcquired+65$2.33+$151.4555,871Direct
Dec 2, 2022Common StockPPurchaseAcquired+65$2.31+$150.1555,936Direct
Dec 5, 2022Common StockPPurchaseAcquired+65$2.19+$142.3556,001Direct
Dec 6, 2022Common StockPPurchaseAcquired+65$2.19+$142.3556,066Direct
Dec 7, 2022Common StockPPurchaseAcquired+65$2.18+$141.756,131Direct
Dec 8, 2022Common StockPPurchaseAcquired+65$2.19+$142.3556,196Direct
Dec 9, 2022Common StockPPurchaseAcquired+65$2.15+$139.7556,261Direct
Dec 12, 2022Common StockPPurchaseAcquired+65$2.14+$139.156,326Direct
Dec 13, 2022Common StockPPurchaseAcquired+120$2.18+$261.656,446Direct
Dec 14, 2022Common StockPPurchaseAcquired+120$2.21+$265.256,566Direct
Dec 15, 2022Common StockPPurchaseAcquired+60$2.24+$134.456,626Direct
Dec 16, 2022Common StockPPurchaseAcquired+100$2.22+$22256,726Direct
Dec 19, 2022Common StockPPurchaseAcquired+250$2.21+$552.556,976Direct
Dec 20, 2022Common StockPPurchaseAcquired+200$2.31+$46257,176Direct
Dec 21, 2022Common StockPPurchaseAcquired+180$2.22+$399.657,356Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)